Halozyme Therapeutics Announces Executive & Director Changes
Ticker: HALO · Form: 8-K · Filed: Oct 6, 2025 · CIK: 1159036
| Field | Detail |
|---|---|
| Company | Halozyme Therapeutics, Inc. (HALO) |
| Form Type | 8-K |
| Filed Date | Oct 6, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $600,000, $500,000 |
| Sentiment | neutral |
Sentiment: neutral
Topics: management-change, compensation, governance
Related Tickers: HALO
TL;DR
Halozyme's board is shuffling execs and directors, watch for new comp plans.
AI Summary
On October 1, 2025, Halozyme Therapeutics, Inc. filed an 8-K report detailing changes in its executive and director compensation arrangements. The filing also announced the election of new directors and the departure of existing ones, alongside the appointment of certain officers.
Why It Matters
Changes in executive and director roles, along with compensation adjustments, can signal shifts in company strategy or governance that may impact shareholder value.
Risk Assessment
Risk Level: medium — Changes in leadership and compensation can introduce uncertainty and signal potential strategic shifts.
Key Players & Entities
- HALOZYME THERAPEUTICS, INC. (company) — Registrant
- October 1, 2025 (date) — Date of Earliest Event Reported
- Delaware (jurisdiction) — State of Incorporation
- 88-0488686 (identifier) — I.R.S. Employer Identification No.
- 12390 El Camino Real (address) — Principal Executive Office Address
- San Diego (location) — City of Principal Executive Office
- California (state) — State of Principal Executive Office
- 92130 (zip_code) — Zip Code of Principal Executive Office
FAQ
What specific executive positions saw changes?
The filing indicates changes related to 'Certain Officers' but does not specify which positions were affected in this excerpt.
Were there any specific reasons cited for director departures?
The filing mentions the 'Departure of Directors' but does not provide specific reasons for these departures in the provided text.
What are the new compensation arrangements for officers?
The filing notes 'Compensatory Arrangements of Certain Officers' but the details of these arrangements are not included in this excerpt.
When was the earliest event reported in this 8-K?
The earliest event reported in this 8-K filing was on October 1, 2025.
What is Halozyme Therapeutics, Inc.'s primary business?
Halozyme Therapeutics, Inc. is in the business of Biological Products (No Diagnostic Substances), SIC code 2836.
Filing Stats: 672 words · 3 min read · ~2 pages · Grade level 11.8 · Accepted 2025-10-06 16:58:17
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value HALO The Nasdaq Stock Market
- $600,000 — lary as Chief Operating Officer will be $600,000 and she will be eligible to participate
- $500,000 — will receive an equity award valued at $500,000 delivered 50% in stock options and 50%
Filing Documents
- halo-20251001.htm (8-K) — 31KB
- halo-20251001_g1.jpg (GRAPHIC) — 15KB
- 0001159036-25-000036.txt ( ) — 172KB
- halo-20251001.xsd (EX-101.SCH) — 2KB
- halo-20251001_lab.xml (EX-101.LAB) — 21KB
- halo-20251001_pre.xml (EX-101.PRE) — 12KB
- halo-20251001_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Halozyme Therapeutics, Inc. (Registrant) Dated: October 6, 2025 By: /s/ Mark Snyder Mark Snyder Senior Vice President, General Counsel and Corporate Secretary